Article Sidebar

PDF
Date Published: 10/02/2023
Abstract Views: 459
Views PDF: 149
DOI: https://doi.org/10.51298/vmj.v520i1B.3830
Issue
Vol. 520 No. 1B (2022)
Section
Các bài báo
How to Cite
Thị Thúy Hằng, N. ., Thị Thái Hòa, N. ., Đình Anh, T. ., & Thị Thanh Nhàn, Đào . (2023). THE RESULT OF SURGERY AND ADJUVANT PLATINUM DOUBLET CHEMOTHERAPY FOR STAGE IB-IIIA NON-SMALL-CELL LUNG CANCER. Vietnam Medical Journal, 520(1B). https://doi.org/10.51298/vmj.v520i1B.3830

THE RESULT OF SURGERY AND ADJUVANT PLATINUM DOUBLET CHEMOTHERAPY FOR STAGE IB-IIIA NON-SMALL-CELL LUNG CANCER

Nguyễn Thị Thúy Hằng1,, Nguyễn Thị Thái Hòa1, Trần Đình Anh2, Đào Thị Thanh Nhàn1
1 Vietnam National Cancer Hospital
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objectives: Assess clinical, subclinical characteristics of stage IB-IIIA non-small-cell lung cancer patients. Evaluating the result of adjuvant chemotherapy vinorelbine/ pemetrexed plus cisplatin in completed resected NSCLC IB-IIIA. Patients and Methods: Descriptive study of 60 patients with stage IB-IIIA resesected non-small-cell lung cancer were received adjuvant vinorelbine/ pemetrexed plus cisplatin chemotherapy from K hospital, 01/2019 to 9/2022. Results: Clinical characteristics: The mean age of 59,52 years old, ratio male : female= 2,7 :1. 21 (35,0%) patients had stage IB disease, 32 (53,3%)  had stage II, and 7 (11,7%) had stage IIIA disease. The major histological type was adenocarcinoma (76,7%). Treating with vinorelbin-cisplatin was 50% and 50% pemetrexed-cisplatin. Treatment results: Mean of disease free survival was 30,5 ± 1,67 months. DFS of vinorelbin-cisplatin or pemetrexed-cisplatin was no different. Vinorelbin-cisplatin caused hematologic toxic effects including neutropenia in 60%. The most commmon nonhematologic toxic effect of those regimens were nausea, vomiting (50,0%). Pemetrexed-cisplatin caused hematologic toxic effects including neutropenia in 60%. The most commmon nonhematologic toxic effect of those regimens were nausea, vomiting 45%.

Article Details

Keywords

Non-small-cell lung cancer (NSCLC), vinorelbine, cisplatin, adjuvant chemotherapy NSCLC

References

1. GS.TS Trần Văn Thuấn Ung thư phổi không tế bào nhỏ. Hướng dẫn chẩn đoán và điều trị bệnh ung thư thường gặp. Nhà xuất bản Y học, Hà Nội, 92–105.
2. Hiro Ken et al, (2019), Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study, ASCO 2019.
3. Pepe C., Hasan B., Winton T.L. và cộng sự. (2007). Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol, 25(12), 1553–1561.
4. Douillard J.-Y., Tribodet H., Aubert D. và cộng sự. (2010). Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5(2), 220–228.